Specific allergen immunotherapy use in 2012: an Irish paediatric surveillance unit (IPSU) study

Hdl Handle:
http://hdl.handle.net/10147/303555
Title:
Specific allergen immunotherapy use in 2012: an Irish paediatric surveillance unit (IPSU) study
Authors:
Neary, E; Hourihane, B
Publisher:
Irish Medical Journal (IMJ)
Journal:
Irish Medical Journal (IMJ)
Issue Date:
Oct-2013
URI:
http://hdl.handle.net/10147/303555
Item Type:
Article
Language:
en
Description:
Specific immunotherapy (SIT) is a disease modifying treatment for allergic rhinitis (AR), with its benefits most evident in those who are refractory to medical treatment. It is used less frequently in UK than Europe/US. No data exist on SIT use in Ireland. We audited paediatric practice to evaluate patient selection, SIT modalities and adverse events (A.E.). A 9 item questionnaire was sent to Irish paediatricians, identified via the Irish Paediatric Surveillance Unit (IPSU) mailing list. 58 children have undertaken SIT (Subcutaneous SCIT =3, Sublingual = 55). This represents 0.01% of Irish children estimated to have AR. 33 (56%) had asthma; 18 (55%) had perennial asthma, 7 (21%) seasonal asthma. Adverse events occurred in 5 cases (8.6%). Three treatments (3-5%) were discontinued as a result. SIT is available across Ireland, though only extremely small numbers of children with AR are being treated yet. Co-morbid asthma is frequent and does not increase adverse events. This audit will raise awareness of SIT use for AR in Ireland.
Keywords:
RHINITIS; ALLERGY; CHILD

Full metadata record

DC FieldValue Language
dc.contributor.authorNeary, Een_GB
dc.contributor.authorHourihane, Ben_GB
dc.date.accessioned2013-10-17T16:53:38Z-
dc.date.available2013-10-17T16:53:38Z-
dc.date.issued2013-10-
dc.identifier.urihttp://hdl.handle.net/10147/303555-
dc.descriptionSpecific immunotherapy (SIT) is a disease modifying treatment for allergic rhinitis (AR), with its benefits most evident in those who are refractory to medical treatment. It is used less frequently in UK than Europe/US. No data exist on SIT use in Ireland. We audited paediatric practice to evaluate patient selection, SIT modalities and adverse events (A.E.). A 9 item questionnaire was sent to Irish paediatricians, identified via the Irish Paediatric Surveillance Unit (IPSU) mailing list. 58 children have undertaken SIT (Subcutaneous SCIT =3, Sublingual = 55). This represents 0.01% of Irish children estimated to have AR. 33 (56%) had asthma; 18 (55%) had perennial asthma, 7 (21%) seasonal asthma. Adverse events occurred in 5 cases (8.6%). Three treatments (3-5%) were discontinued as a result. SIT is available across Ireland, though only extremely small numbers of children with AR are being treated yet. Co-morbid asthma is frequent and does not increase adverse events. This audit will raise awareness of SIT use for AR in Ireland.en_GB
dc.language.isoenen
dc.publisherIrish Medical Journal (IMJ)en_GB
dc.subjectRHINITISen_GB
dc.subjectALLERGYen_GB
dc.subjectCHILDen_GB
dc.titleSpecific allergen immunotherapy use in 2012: an Irish paediatric surveillance unit (IPSU) studyen_GB
dc.typeArticleen
dc.identifier.journalIrish Medical Journal (IMJ)en_GB
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.